Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Jason D GoldmanDavid C B LyeDavid S HuiKristen M MarksRaffaele BrunoRocio MontejanoChristoph D SpinnerMassimo GalliMi-Young AhnRonald G NahassYao-Shen ChenDevi SenGuptaRobert H HylandAnu O OsinusiHuyen CaoChristiana BlairXuelian WeiAnuj GaggarDiana M BrainardWilliam J TownerJose MuñozKathleen M MullaneFrancisco M MartyKaren T TashimaGeorge DiazAruna Subramaniannull nullPublished in: The New England journal of medicine (2020)
In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.).
Keyphrases
- mechanical ventilation
- coronavirus disease
- sars cov
- acute respiratory distress syndrome
- intensive care unit
- phase iii
- early onset
- clinical trial
- study protocol
- respiratory failure
- respiratory syndrome coronavirus
- phase ii
- extracorporeal membrane oxygenation
- randomized controlled trial
- double blind
- placebo controlled